Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma.

Proficio Capital Partners LLC bought a new stake in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) in the 4th ...

Agilent offers a broad variety of high-quality workflow solutions for various applications within diagnostics, clinical & research applications in cancer, inherited, and infectious disease.

These are the recent developments in Waters Corp. and Agilent Technologies Inc. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Agilent Technologies Inc. and Synthego Corp. sparred Friday over whether Agilent patents related to a key component of the CRISPR DNA editing system were anticipated by a third company’s earlier-filed ...

SANTA CLARA, Calif., March 10, 2025--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

SANTA CLARA, Calif., February 19, 2025--Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April ...